Plasma miR371 test for testis cancer patients and real-world care patterns
Official title: Plasma miR371 clinical utility and mapping real-world management of testis cancer patients: Extended analysis for clinical utility and secondary use of data of the SWOG 1823/CCTG GCC1 clinical trial
Funded at Provincial Health Services Authority · NIH-10976966 · Data updated 2026-11-12
A study to see if a blood biomarker (miR371) can better detect germ cell tumor recurrence and to understand how testis cancer is managed in real-world clinics.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Provincial Health Services Authority NIH-funded |
| Lab location | 1 site (Vancouver, Canada) |
| Project start | April 1, 2026 |
| Project end | March 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $383,151 |
| NIH project number | 4R37CA264798-04 |
| Project ID | NIH-10976966 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with germ cell tumor who are being monitored for recurrence, and centers participating in S1823/SWOG trials.
✕Less likely to help
Patients not currently managed with germ cell tumors or those not enrolled in the S1823/SWOG cohort may not benefit.
What this research studies
This project will test a new, more sensitive method to measure miR371 in blood and compare it to the current approach for predicting relapse in testis cancer. It will also use existing data from the S1823 trial to map how patients are diagnosed, treated, and followed in Canada and the United States. By combining lab findings with real-world clinical data, the study aims to clarify if miR371 can improve monitoring and outcomes for patients with germ cell tumors. The research leverages a leading position in the S1823 trial to access rich patient information and specimens.
Why it matters
Potential benefit: If successful, the approach could improve early detection of relapse and inform more precise follow-up care for testis cancer patients.
How similar studies have gone: Previous work shows miR371 has potential as a relapse marker, with further validation needed in subclinical stages.
Where this research is happening
-
Provincial Health Services Authority
Vancouver, Canada Active
Researchers
- Principal investigator: Nappi, Lucia — Provincial Health Services Authority
- Study coordinator: Nappi, Lucia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.